AstraZeneca Seeks Added Seroquel Approval

(July 18, 2006) -- AstraZeneca Plc. said Tuesday it filed an application with the U.S. Food and Drug Administration for a sustained-release version of its schizophrenia treatment, Seroquel. The drug, launched in 1997, is used to treat acute manic episodes associated with bipolar disorder and schizophrenia. The current immediate-release formula tablets are approved for dosing two to three times a day. Global sales totaled $2.8 billion last year.

The new formulation involves a once-daily tablet which the company said was shown to be effective as early as the second day of treatment in clinical trials.

U.K.-based AstraZeneca said it plans to seek approval in the European Union toward the end of the year.

Sources: AstraZeneca Press Release, Reuters

Last updated: 7/06

Related Information:

• Seroquel Study Gives Hope For Beating Depression In Bipolar Disorder
• AstraZeneca Looks to Expand Seroquel's Uses
• Psychiatric Drugs Linked with Metabolic Problems
• Seroquel May Improve Life for Bipolar Patients
• Seroquel Treats Bipolar Disorder Mania and Depression
• SEROQUEL Examined as Treatment for Depressive Episodes Associated with Bipolar Disorder
• Seroquel With Lithium or Divalproex For Bipolar Mania
• Double Boost for Seroquel
• Seroquel Approved for Treatment of Acute Mania Associated With Bipolar Disorder
• How To Survive Bipolar Disorder
• Family-Focused Therapy Helps Bipolar Patients Cope
• Seroquel Approved for Treatment of Acute Mania Associated With Bipolar Disorder

back to top ~ bipolar news index ~ send page to a friend